Johnson & Johnson presenta a la Agencia Europea de Medicamentos una solicitud de aprobación de la formulación subcutánea de RYBREVANT®▼ (amivantamab) para el tratamiento de pacientes con cáncer de pulmón no microcítico con mutación del EGFR
June 05, 2024 10:14 ET
|
Janssen Cilag International NV
La solicitud está respaldada por los datos del estudio de fase 3 PALOMA-3 presentado en la Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO)1 La nueva formulación demostró no ser...
Johnson & Johnson soumet à l’Agence européenne des médicaments une demande d’approbation de la formulation sous-cutanée de RYBREVANT®▼ (amivantamab) pour le traitement des patients atteints d’un cancer du poumon non à petites cellules avec mutation de l’EGFR
June 05, 2024 10:12 ET
|
Janssen Cilag International NV
La demande est étayée par les données de l’étude de Phase III PALOMA-3 présentées lors de la réunion annuelle de l’American Society of Clinical Oncology (« ASCO »)1 La nouvelle formulation a montré...
DARZALEX® (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma
June 03, 2024 16:10 ET
|
Janssen Cilag International NV
88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with daratumumab subcutaneous...
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma
June 03, 2024 16:02 ET
|
Janssen Cilag International NV
73 percent reduction in risk of disease progression or death seen with cilta-cel in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy1 ...
Late-breaking results from PALOMA-2 study of subcutaneous RYBREVANT®▼ (amivantamab) in combination with lazertinib show clinically meaningful antitumour response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer
June 03, 2024 14:44 ET
|
Janssen Cilag International NV
Significantly lower infusion-related reactions seen with subcutaneous amivantamab compared with intravenous administration in new Phase 2 data1BEERSE, BELGIUM, June 03, 2024 (GLOBE NEWSWIRE) --...
TECVAYLI®▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma
June 03, 2024 08:19 ET
|
Janssen Cilag International NV
New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing1 Separate analyses from the MajesTEC-1 and...
Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT®▼ (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer
May 31, 2024 17:50 ET
|
Janssen Cilag International NV
Submission is supported by data from the Phase 3 PALOMA-3 study featured at the American Society of Clinical Oncology (ASCO) Annual Meeting1New formulation showed non-inferiority to intravenous...
RYBREVANT®▼ (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
May 31, 2024 17:21 ET
|
Janssen Cilag International NV
Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease1Landmark Phase 3 MARIPOSA...
TAR-200-Monotherapie zeigt vollständige Ansprechrate von über 80 Prozent bei Patienten mit nicht-muskelinvasivem Hochrisiko-Harnblasenkarzinom
May 10, 2024 06:44 ET
|
Janssen Cilag International NV
Neue Daten aus der Phase-IIb-Studie SunRISe-1 zeigen schnelles Erreichen eines vollständigen Ansprechens (Complete Response, CR) mit 98 Prozent der Patienten, die innerhalb von 12 Wochen eine CR...
La monoterapia con TAR-200 mostra un tasso di risposta completa superiore all’80 per cento nei pazienti con tumore della vescica non muscolo-invasivo ad alto rischio
May 10, 2024 06:44 ET
|
Janssen Cilag International NV
I nuovi dati dello studio di Fase 2b SunRISe-1 mostrano un rapido raggiungimento della risposta completa (CR), con il 98 per cento dei pazienti che raggiunge la CR entro 12 settimane1 TAR-200...